Hetzer R, Schüler S, Warnecke H, Süthoff U, Lang W, Wonigeit K, Herrmann G, Hepp A, Witt E, Schaps D
Herz. 1985 Jun;10(3):149-56.
Within the spectrum of presently accepted candidates for heart transplantation, end-stage heart failure in dilated cardiomyopathy has become the principle indication. Although several indicators of poor prognosis have been specified, the decision for heart transplantation is primarily made on clinical grounds. Expected long-term survival after transplantation is 60 to 80% at one year and more than 50% at five years. Since July, 1983, 50 patients underwent orthotopic heart transplantation, 38 of whom had been suffering from dilated cardiomyopathy. Ages ranged from nine to 54 years with a mean of 40 years. At present, 38 patients are alive, 34 are discharged from hospital, 14 have returned to work or school. Physical capacity and cardiac function are normal. There was no difference between the cardiomyopathy patients and the coronary artery disease patients with respect to rate and severity of rejection episodes, infection and long-term findings. Heart transplantation is considered a promising routine treatment for end-stage heart failure in particular in younger patients with dilated cardiomyopathy.
在目前被认可的心脏移植候选者范围内，扩张型心肌病所致的终末期心力衰竭已成为主要适应症。尽管已明确了几个预后不良的指标，但心脏移植的决定主要基于临床依据。移植后预期的一年长期生存率为60%至80%，五年生存率超过50%。自1983年7月以来，50例患者接受了原位心脏移植，其中38例患有扩张型心肌病。年龄范围为9岁至54岁，平均年龄40岁。目前，38例患者存活，34例出院，14例已恢复工作或上学。身体能力和心功能正常。心肌病患者与冠状动脉疾病患者在排斥反应发作的发生率和严重程度、感染及长期结果方面没有差异。心脏移植被认为是治疗终末期心力衰竭的一种有前景的常规疗法，特别是对于患有扩张型心肌病的年轻患者。
